wed alway assumpt gs strategi get smaller
get bigger earli novemb wed sens renew interest
 tuck-in deal activ pick recent month appear
widen net pursuit growth
last week addit news would acquir chicago-bas dry-
clean start-up pressbox press report name among list potenti bidder
bristol-my squibb french over-the-count drug busi upsa come
month news sourc surfac suggest may bid pfizer
consum healthcar busi subsequ announc
acquir merck consum health manag yet formal
dismiss interest latest set comment point
valuat main impedi sale sens deal two
could well still play compani eventu abl meet price
iron wouldnt first time attempt acquir brand
current shop within pfizer consum healthcar busi us
whove around long enough rememb made advanc toward
american product warner-lambert goal rapidli transform
 one world largest pharmaceut compani howev merger talk
fizzl shortli becam public end acquir warner-lambert
interestingli also went acquir american product renam
wyeth almost decad later
high level combin pfizer consum healthcar busi today
would look much like repeat past still think import note
also key differ current situat took place
compani back late note revisit histori compar
contrast addit also highlight risk see
doubl consum health industri
pg quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
equal weight see invest
need plan make product innov
market brand seemingli price
requir fund time drive sustain stronger
assum pg trade base case ep
estim repres premium
assum pg trade downsid case
ep estim line consum stapl
peer assum peer set trade
discount market vs current
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
made decis say activ manag see opportun
acquir potenti new technolog capabl potenti compani
space exist core categori adjac one leverag
capabl ceo david taylor earn call
long-stand adag industri struggl slow top-lin growth
look extern way improv trend case nearli four year sinc
compani first announc plan re-focu core divest half
brand portfolio organ sale trend yet reflect notabl inflect cours
time period global categori growth also slow still percent gs
busi hold gain share improv wed alway
assumpt gs strategi get smaller get bigger earli
novemb wed sens renew interest tuck-in deal activ pick
recent month appear widen net pursuit growth
last week addit news would acquir chicago-bas dry-clean
start-up pressbox press report name among list potenti bidder bristol-
myer squibb french over-the-count drug busi upsa would mark third
over-the-counter asset link three month rekindl curios
around potenti attract doubl categori recal
april news sourc surfac suggest may look acquir pfizer consum
healthcar busi see link although ensu thereaft acquisit
merck consum health instead still manag yet formal dismiss
interest latest set comment point valuat
main impedi sale sens deal could well
still play compani eventu abl meet price
sure gs interest over-the-counter new compani involv space
date back acquisit norwich eaton pharmaceut maker pharmaceut
over-the-counter brand pepto-bismol chlorasept
categories/adjac over-the-counter space remain consist interest rel
other tuck-in prestig male groom zirh art shave beauti freder
fekkai ddf part eventu divest give us paus around
strateg longev gs latest two bolt-on natur person snowberri
nativ point iron wouldnt first time attempt acquir
brand current shop within pfizer consum health busi
us whove around long enough rememb effort stem
product over-the-counter brand advil prepar among other warner-lambert over-the-counter
brand listerin lubriderm goal rapidli transform one
world largest pharmaceut compani howev merger talk fizzl shortli
becam public end acquir warner-lambert interestingli also
went acquir american product renam wyeth decad later
histori repeat high level combin pfizer
consum healthcar busi would look much like repeat past still think
import note also key differ current situat
took place compani back late note revisit
histori compar contrast
parallel fundament perform gs core busi today
 go path acquir pfizer consum healthcar unit
markedli similar strategi counter dynam howev think manag
aspir compani motiv factor behind healthcar deal today would
look differ past natur asset question
corrobor thought process
late gs top-lin growth slow low single-digit rate
heel ceo john pepper retir appoint durk jager
compani new ceo mr jager veteran spent
career handl busi outsid task bring
turnaround compani fundament
similarli past decad also seen dramat weaken top-lin trend
low single-digit clip past three year see particularli weak volatil
perform david taylor appoint ceo succeed lafley tenur
year experi belt mr taylor given rein
struggl compani expect gener recoveri
mr jager mr taylor appoint ceo period
remark fundament under-perform compani
differ aspir outcom
mr jager direct instat aggress perform goal hindsight
push organ much fast gs new strateg plan call
ramp revenu earn growth ambiti goal even
context rel stronger industri growth rate time revenu
earn growth part six-year global reorgan mission organ
aim jumpstart growth made seri rapid dramat chang includ
seek opportun new categori market increas relianc
unfortun chang prove radic organ adopt
reorgan transplant mani experienc employe dilut much
compani institut knowledg base relationship retail custom suffer
particularli western europ sever gs product delist major
account franc germani forecast spend stretch object pressur
margin volum growth didnt materi plan new product initi
realli quest new world blockbust product dryel fruit
swiffer receiv disproportion percentag market dollar resourc
expens franchis brand like tide alway mid compani
lose market share seven top nine categori market
lower earn expect four time two quarter
contrast sens urgenc today would argu
model less stress rel past recal ask long-term object
recent confer cfo jon moeller comment point time set
specif high-reach goal risk mislead impli know
notion know chang go need make next year
year think old-fashion sure without finit time-frame
specif goal defin turnaround pace gs recoveri mr taylor
leadership arguabl frustratingli slow top-lin growth still trend low-
singl digit problem child busi male groom global babi
total compani sale remain challeng despit innov and/or price adjust
tougher far complex oper environ partli blame shift industri
dynam grow mistrust big brand retail transform rise privat label
local competit creat new challeng compani navig see
 consum stapl sphere despair backdrop would
argu lack overli aggress stretch goal least allow
avoid past pitfal much fast measur inch mile
approach bring chang prove sustain
 gs interest warner-lambert american product came time
compani activ pursu transform acquisit quest growth
late specul began circul approach gillett
take-over indic gs willing make big potenti dilut acquisit enter
groom deal gillett didnt materi differ
leadership enter pet food acquisit iam
deal tag exceed mark transform acquisit date time
much smaller scale mm compani also acquir recoveri engin give
 entri water-filt busi vi vi pur brand
shortli pur news leak consid step take-over fight
white knight pharmaceut compani warner-lambert american
product attempt fight hostil bid mark anoth radic move
 would lead increas compani revenu base whilst
transform second-biggest pharmaceut concern market leader
over-the-count medicin overnight end howev sharpli neg stock
reaction dilut concern gs share price drop three trade session
follow leak push manag halt negoti end acquir
warner-lambert interestingli also went acquir american
product renam wyeth decad later
contrast acquir pfizer consum healthcar busi today would much
smaller undertak natur extens gs exist portfolio asset
question combin pharmaceut over-the-count brand
pfizer consum healthcar busi consist sole over-the-count medic
focu gs exist healthcar busi recal built small
pharmaceut divis asacol hd actonel enablex main product
compani sold warner chilcott revenu base
asset would far less transform term size repres gs
broader industri growth within consum healthcar arena slow discuss
recent global deep-div consum healthcar space see global
consum heal thyself on-line corner store categori growth broader
industri slow mid single-digit clip low single-digit last
month given on-going disrupt drug-stor channel specif brick mortar
drug-retail resort destock price pressur increas focu
privat label effort protect growth margin consum shift on-line
retail face even greater pressur sub-categori sport nutrit
vitamins/dietari supplement digit penetr fulli total
over-the-counter less impact forc drive slowdown digit
penetr tradit over-the-counter categori gastro pain cough cold still
hover addit privat label share categori increas
past decad trend appear hit plateau
recent three year suggest privat label option thu far peak regard
concern futur disrupt across board context pfizer
consum healthcar portfolio split roughli evenli vitamins/suppl
tradit over-the-counter sure tough dodg disrupt categori today
aforement dynam becom ubiquit oper cpg univers still
exposur vitamins/suppl come risk low barrier entri
gener greater consum willing experi categori versu cold/cough
allergi relief medic drive signific brand prolifer new entrant
case over-the-counter drug believ nascenc deliveri infrastructur e-
commerc channel perhap protect categori threat digit
expans greater extent categori quest immedi symptom
relief drive major purchas point recent move amazon
healthcar arena give us paus specif februari year amazon instat
partnership privat label over-the-counter drug manufactur launch basic
line consum health product two week ago amazon acquir pillpack
on-line pharmaci enabl user buy medic pre-mad dose see
combin two event least potenti exacerb
headwind see tradit drug-stor channel pressur categori
growth addit infrastructur on-line marketplac evolv
shorten deliveri time hour see outsiz impact
lauren lieberman herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
